Careers & Students

Drug development for metabolic diseases

PhD/Honours project

AMP-activated protein kinase (AMPK) is a central regulator of cellular energy metabolism that phosphorylates multiple protein targets to adapt cellular metabolism to energy and nutrient availability. AMPK dysregulation is associated with a range of prevalent metabolic diseases (e.g. type 2 diabetes, cancer and cardiovascular disease), thus huge efforts are being made to develop AMPK-targetting drugs.

AMPK is a heterotrimer complex composed of catalytic a (isoforms a1/2) and regulatory b (b1/2) and g (g1/2/3) subunits. A major problem with current pan AMPK-targetting drugs is they activate AMPK throughout the body, causing off-target effects such as cardiac hypertrophy. Intriguingly, AMPK b2-isoform is found almost exclusively in metabolically-active tissues e.g. liver, adipose and skeletal muscle, the latter of which is a validated target tissue for improved glucose control in response to pan-AMPK activators (Merck, Pfizer). Our aim is to develop b2-specific AMPK activators to trigger AMPK signalling in these tissues without complications associated with off-target effects.

As part of our team of 5 postdoctoral scientists, you will receive training from experts in biochemistry, cell biology, x-ray crystallography and mass spectrometry. The team adopts a collaborative approach with studies regularly published in high impact journals.

Supervised by:

  • A/Prof Jon Oakhill
  • Prof Bruce E. Kemp
  • Disease Focus:

  • Type 2 diabetes
  • Cancer
  • Heart disease
  • Research Unit:

  • Metabolic signalling
  • For further information about this project, contact: [email protected]